Unknown

Dataset Information

0

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.

ABSTRACT:

SUBMITTER: Declercq J 

PROVIDER: S-EPMC8555973 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.

Declercq Jozefien J   Van Damme Karel F A KFA   De Leeuw Elisabeth E   Maes Bastiaan B   Bosteels Cedric C   Tavernier Simon J SJ   De Buyser Stefanie S   Colman Roos R   Hites Maya M   Verschelden Gil G   Fivez Tom T   Moerman Filip F   Demedts Ingel K IK   Dauby Nicolas N   De Schryver Nicolas N   Govaerts Elke E   Vandecasteele Stefaan J SJ   Van Laethem Johan J   Anguille Sebastien S   van der Hilst Jeroen J   Misset Benoit B   Slabbynck Hans H   Wittebole Xavier X   Liénart Fabienne F   Legrand Catherine C   Buyse Marc M   Stevens Dieter D   Bauters Fre F   Seys Leen J M LJM   Aegerter Helena H   Smole Ursula U   Bosteels Victor V   Hoste Levi L   Naesens Leslie L   Haerynck Filomeen F   Vandekerckhove Linos L   Depuydt Pieter P   van Braeckel Eva E   Rottey Sylvie S   Peene Isabelle I   Van Der Straeten Catherine C   Hulstaert Frank F   Lambrecht Bart N BN  

The Lancet. Respiratory medicine 20211029 12

<h4>Background</h4>Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interleukin (IL)-1 and IL-6 blockade have been proposed as therapeutic strategies in COVID-19, but study outcomes have been conflicting. We sought to study whether blockade of the IL-6 or IL-1 pathway shortened the time to clinical improvement in patients with COVID-19, hypoxic respiratory failure, and signs of systemic cytokine release syndrome.<h4>Methods</h4>We did a prospective, multicentre,  ...[more]

Similar Datasets

Unknown Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
| S-EPMC7267751 | biostudies-literature
Unknown Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection.
| S-EPMC8092681 | biostudies-literature
Unknown Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review).
| S-EPMC7690237 | biostudies-literature
Unknown Anti-inflammatory mechanisms of the novel cytokine interleukin-38 in allergic asthma.
| S-EPMC7264207 | biostudies-literature
Unknown Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents.
| S-EPMC7443334 | biostudies-literature
Unknown Repurposing of drugs targeting the cytokine storm induced by SARS-CoV-2.
| S-EPMC10953344 | biostudies-literature
Unknown Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019.
| S-EPMC7314334 | biostudies-literature
Unknown A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials.
| S-EPMC8079380 | biostudies-literature
Unknown In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome.
| S-EPMC6220327 | biostudies-literature
Unknown Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model.
| S-EPMC4623119 | biostudies-literature